12th Annual IBA World Life Sciences Conference

3 Jun - 5 Jun 2026

Session information

PANEL FIVE - What are the most challenging contractual issues when discussing licensing and other agreements with strategic partners?

Description

When technology and intellectual property rights are core assets, licensing to and from commercial partners is an essential part of a company's strategy. Licensing generates revenue, in addition to enhancing a company's value. Leveraging on in-house R&D capabilities, licensing in and out to strategic partners may secure business development and increase the probability for new product launches. Figuring out the right steps to take is challenging and requires a dedicated strategy. Join in-house and counselling legal experts in all intellectual property, regulatory and commercial matters, with long-term experience in the field of life sciences, as they discuss issues relating to licensing and share with participants their knowledge and insight.

Session / Workshop Chair(s)

Gustavo Alcocer Olivares, Mexico City, Mexico
Lorenza Ferrari-Hofer Schellenberg Wittmer, Zürich, Switzerland; Intellectual Property and Media Law Committee Liaison Officer, Healthcare and Life Sciences Law Committee

Speakers

Gesilaine Bernardi Astellas Pharma , São Paulo, Brazil
Vanessa Burrows Simpson Thacher & Bartlett LLP, Washington, District of Columbia, USA; Vice Chair, Life Sciences Subcommittee
Camila Marchant Astrazeneca, São Paulo, Brazil
Maren Müller Grünenthal Group, Aachen, Germany